Cuba-Rushford Junior/Senior High School has announced the honor rolls for the second quarter of the 2024–25 school year ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...

"I'm not much of a crier," Hawks football coach Tony Woolfolk said. "But I was so proud and loved those guys so much that I ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Fortunately, we are making some progress as organizations such as the Partnership for Advancing Clinical Trials (PACT) ...

Stretch Zone, the nation's leader in practitioner-assisted stretching, is stepping confidently into 2025 with a focus on innovation, growth, and strategic investments. Following a strong 2024, the ...